Trial Outcomes & Findings for Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes (NCT NCT04433975)
NCT ID: NCT04433975
Last Updated: 2025-07-09
Results Overview
In this study, "retention on buprenorphine treatment" was defined as the time until a participant stopped taking their medication for 7 or more days in a row. This information was collected using a calendar recall method, the TimeLine Follow-Back (TLFB) measure at 3 months. The average number of days participants remained on buprenorphine before this happened was calculated, using the data collected at 3-month follow-up.
COMPLETED
NA
200 participants
3-months post enrollment
2025-07-09
Participant Flow
IRB approval from the University of Michigan (UM) was obtained in February 2020 with remote recruitment changes approved in June 2020. Several of the recruitment strategies used were in person recruitment at local buprenorphine clinics; posted flyers at community locations; targeted advertising on Facebook, Instagram, and Craigslist; posts on the UMHealthResearch.org page; advertising on websites that target patients in recovery; review of health records at UM and Ann Arbor VA Healthcare System
Participant milestones
| Measure |
Psychosocial Pain Management (PPMI)
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Completed Baseline and Randomized
STARTED
|
98
|
102
|
|
Completed Baseline and Randomized
COMPLETED
|
98
|
102
|
|
Completed Baseline and Randomized
NOT COMPLETED
|
0
|
0
|
|
1-month Follow Up
STARTED
|
98
|
102
|
|
1-month Follow Up
Completed Interview
|
81
|
82
|
|
1-month Follow Up
COMPLETED
|
76
|
76
|
|
1-month Follow Up
NOT COMPLETED
|
22
|
26
|
|
3-month Follow Up
STARTED
|
97
|
101
|
|
3-month Follow Up
Completed Interview
|
78
|
84
|
|
3-month Follow Up
COMPLETED
|
74
|
77
|
|
3-month Follow Up
NOT COMPLETED
|
23
|
24
|
|
6-month Follow Up
STARTED
|
94
|
101
|
|
6-month Follow Up
Completed Interview
|
72
|
74
|
|
6-month Follow Up
COMPLETED
|
70
|
72
|
|
6-month Follow Up
NOT COMPLETED
|
24
|
29
|
|
9-month Follow Up
STARTED
|
93
|
100
|
|
9-month Follow Up
Completed Interview
|
69
|
70
|
|
9-month Follow Up
COMPLETED
|
66
|
63
|
|
9-month Follow Up
NOT COMPLETED
|
27
|
37
|
|
12-month Follow Up
STARTED
|
93
|
99
|
|
12-month Follow Up
Completed Interview
|
68
|
73
|
|
12-month Follow Up
COMPLETED
|
66
|
68
|
|
12-month Follow Up
NOT COMPLETED
|
27
|
31
|
Reasons for withdrawal
| Measure |
Psychosocial Pain Management (PPMI)
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
1-month Follow Up
Withdrawal by Subject
|
1
|
1
|
|
1-month Follow Up
Lost to Follow-up
|
21
|
25
|
|
3-month Follow Up
Lost to Follow-up
|
20
|
24
|
|
3-month Follow Up
Death
|
1
|
0
|
|
3-month Follow Up
Withdrawal by Subject
|
2
|
0
|
|
6-month Follow Up
Lost to Follow-up
|
23
|
28
|
|
6-month Follow Up
Withdrawal by Subject
|
1
|
1
|
|
9-month Follow Up
Lost to Follow-up
|
27
|
36
|
|
9-month Follow Up
Death
|
0
|
1
|
|
12-month Follow Up
Lost to Follow-up
|
27
|
31
|
Baseline Characteristics
Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes
Baseline characteristics by cohort
| Measure |
Psychosocial Pain Management (PPMI)
n=98 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=102 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
Total
n=200 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
42.37 years
STANDARD_DEVIATION 10.79 • n=5 Participants
|
44.68 years
STANDARD_DEVIATION 10.78 • n=7 Participants
|
43.55 years
STANDARD_DEVIATION 10.82 • n=5 Participants
|
|
Sex: Female, Male
Female
|
57 Participants
n=5 Participants
|
58 Participants
n=7 Participants
|
115 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
41 Participants
n=5 Participants
|
44 Participants
n=7 Participants
|
85 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
8 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
88 Participants
n=5 Participants
|
97 Participants
n=7 Participants
|
185 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
12 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
75 Participants
n=5 Participants
|
90 Participants
n=7 Participants
|
165 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
8 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
98 participants
n=5 Participants
|
102 participants
n=7 Participants
|
200 participants
n=5 Participants
|
|
Military Status
|
2 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Brief Pain Inventory (BPI) Score
|
4.7 units on a scale
STANDARD_DEVIATION 2.2 • n=5 Participants
|
4.8 units on a scale
STANDARD_DEVIATION 2.4 • n=7 Participants
|
4.8 units on a scale
STANDARD_DEVIATION 2.3 • n=5 Participants
|
|
Percent days abstinent
|
51.3 percent
STANDARD_DEVIATION 33.2 • n=5 Participants
|
50.9 percent
STANDARD_DEVIATION 34.0 • n=7 Participants
|
51.1 percent
STANDARD_DEVIATION 33.6 • n=5 Participants
|
|
Numeric Rating Scale (NRS-I) Score
|
7.43 units on a scale
STANDARD_DEVIATION 1.28 • n=5 Participants
|
7.55 units on a scale
STANDARD_DEVIATION 1.26 • n=7 Participants
|
7.49 units on a scale
STANDARD_DEVIATION 1.28 • n=5 Participants
|
|
Rapid Opioid Dependence Screen (RODS)
|
6.22 units on a scale
STANDARD_DEVIATION 1.36 • n=5 Participants
|
6.04 units on a scale
STANDARD_DEVIATION 1.52 • n=7 Participants
|
6.13 units on a scale
STANDARD_DEVIATION 1.44 • n=5 Participants
|
|
Severity of Opioid Use Disorder
Mild
|
8 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
|
Severity of Opioid Use Disorder
Moderate
|
11 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
|
Severity of Opioid Use Disorder
Severe
|
79 Participants
n=5 Participants
|
75 Participants
n=7 Participants
|
154 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 3-months post enrollmentIn this study, "retention on buprenorphine treatment" was defined as the time until a participant stopped taking their medication for 7 or more days in a row. This information was collected using a calendar recall method, the TimeLine Follow-Back (TLFB) measure at 3 months. The average number of days participants remained on buprenorphine before this happened was calculated, using the data collected at 3-month follow-up.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=98 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=102 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 3-months
|
81.1 days
Standard Deviation 26.6
|
75.4 days
Standard Deviation 32.3
|
SECONDARY outcome
Timeframe: 12-months post enrollmentIn this study, "retention on buprenorphine treatment" was defined as the time until a participant stopped taking their medication for 7 or more days in a row. This information was collected using a calendar recall method, the TimeLine Follow-Back (TLFB) measure at 12 months. The average number of days participants remained on buprenorphine before this happened was calculated, using the data collected at 12-month follow-up.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=98 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=102 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 12 Months
|
252.1 days
Standard Deviation 135.5
|
236.5 days
Standard Deviation 148.9
|
SECONDARY outcome
Timeframe: 3-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Pain level will be measured using the Numerical Rating Scale for Pain Intensity (NRS-I), an 11-point numeric rating scale (0=no pain, 10= worst pain imaginable), which will be collected at the baseline enrollment assessment and 3-month follow-up. To calculate our measure, we subtracted each participant's score at 3-month assessment and subtracted it from their baseline score. We then averaged calculated average change in scores for each intervention group.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=77 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=77 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Average Change in Self-reported Level of Pain Intensity on the Numerical Rating Scale for Pain Intensity (NRS-I) at 3-month Follow up (Compared to Baseline)
|
-0.7 score on a scale
Standard Deviation 1.4
|
-1.1 score on a scale
Standard Deviation 2.2
|
SECONDARY outcome
Timeframe: 3-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Pain-related functioning will be measured using the pain interference subscale of the Brief Pain Inventory - Short Form (BPI), an 11-point numeric rating scale (0 = no pain/does not interfere, 10 = worst pain imaginable/completely interferes). For this study, an increase in pain-related functioning will be measured as a reduction in the pain interference scale scores over time. The BPI interference subscale measures how much pain has interfered with seven daily activities and will provide a current level of pain-related functioning (past 24-hours) at the 3-month follow-up. BPI pain interference will be calculated as the mean of the seven interference items. For each follow-up time point, the baseline value will be subtracted to obtain a change score.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=74 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=76 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Average Change in Self-Reported Level of Pain Related Functioning on the Brief Pain Inventory - Short Form (BPI) at 3-month Follow up (Compared to Baseline)
|
-0.3 score on a scale
Standard Deviation 2.1
|
-0.8 score on a scale
Standard Deviation 2.2
|
SECONDARY outcome
Timeframe: 3-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Frequency of substance use will be measured using the TimeLine Follow-Back and will be collected at 3-month follow-up. During the administration, the participant will be asked to recall their alcohol and drug use utilizing a calendar-assisted structured interview that provides the participant with temporal cues to increase the accuracy of recall. At each follow-up, data will be collected for the entire period since the previous date of data collection. Percent days abstinent from substances (e.g. alcohol and drugs) will be used as the primary measure of substance use. Values shown are the treatment group average percent of days that participants were abstinent from substances after 3 months follow-up.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=85 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=86 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Percent Days Abstinent From Substance Use on the TimeLine Follow-Back - 3-months
|
76.7 percent of days
Standard Deviation 37.5
|
74.2 percent of days
Standard Deviation 37.8
|
SECONDARY outcome
Timeframe: 12-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Pain level will be measured using the Numerical Rating Scale for Pain Intensity (NRS-I), an 11-point numeric rating scale (0 = no pain, 10 = worst pain imaginable), which will be collected at the baseline enrollment assessment and the 12-month follow-up. For each follow-up time point, the baseline value will be subtracted to obtain a change score.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=66 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=68 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Average Change in Self-reported Level of Pain Intensity on the Numerical Rating Scale for Pain Intensity (NRS-I) at 12-month Follow up (Compared to Baseline)
|
-1.5 score on a scale
Standard Deviation 2.2
|
-1.9 score on a scale
Standard Deviation 2.6
|
SECONDARY outcome
Timeframe: 12-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Pain-related functioning will be measured using the pain interference subscale of the Brief Pain Inventory - Short Form (BPI), an 11-point numeric rating scale (0 = no pain/does not interfere, 10 = worst pain imaginable/completely interferes). For this study, an increase in pain-related functioning will be measured as a reduction in the pain interference scale scores over time. The BPI interference subscale measures how much pain has interfered with seven daily activities and will provide a current level of pain-related functioning (past 24-hours) at the 12-month follow-up. BPI pain interference will be calculated as the mean of the seven interference items. For each follow-up time point, the baseline value will be subtracted to obtain a change score.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=62 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=67 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Average Change in Self-Reported Level of Pain Related Functioning on the Brief Pain Inventory - Short Form (BPI) at 12-month Follow up (Compared to Baseline)
|
-0.6 score on a scale
Standard Deviation 2.9
|
-0.9 score on a scale
Standard Deviation 2.5
|
SECONDARY outcome
Timeframe: 12-months post enrollmentPopulation: Participants were not required to answer every survey question. Number of participants analyzed reflects number of participants who provided data for this survey question.
Frequency of substance use will be measured using the TimeLine Follow-Back and will be collected at the 12-month follow-up. During the administration, the participant will be asked to recall their alcohol and drug use utilizing a calendar-assisted structured interview that provides the participant with temporal cues to increase the accuracy of recall. At each follow-up, data will be collected for the entire period since the previous date of data collection. Percent days abstinent from substances (e.g. alcohol and drugs) will be used as the primary measure of substance use. Values shown are the treatment group average percent of days that participants were abstinent from substances after 12 months follow-up.
Outcome measures
| Measure |
Psychosocial Pain Management (PPMI)
n=68 Participants
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=73 Participants
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Percent Days Abstinent From Substance Use on the TimeLine Follow-Back - 12 Months
|
74.7 percent of days
Standard Deviation 35.2
|
79.6 percent of days
Standard Deviation 32.0
|
Adverse Events
Psychosocial Pain Management (PPMI)
Enhanced Usual Care (EUC)
Serious adverse events
| Measure |
Psychosocial Pain Management (PPMI)
n=98 participants at risk
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=102 participants at risk
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
Psychiatric disorders
Hospitalization - psych
|
4.1%
4/98 • Number of events 5 • 12 months
|
3.9%
4/102 • Number of events 4 • 12 months
|
|
General disorders
Hospitalization - general medical
|
16.3%
16/98 • Number of events 28 • 12 months
|
12.7%
13/102 • Number of events 18 • 12 months
|
Other adverse events
| Measure |
Psychosocial Pain Management (PPMI)
n=98 participants at risk
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
Psychosocial Pain Management (PPMI): The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Enhanced Usual Care (EUC)
n=102 participants at risk
Two individual telephone educational sessions with research study therapist.
Enhanced Usual Care (EUC): The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
|---|---|---|
|
General disorders
Emergency Medical Visit
|
3.1%
3/98 • Number of events 3 • 12 months
|
0.00%
0/102 • 12 months
|
|
General disorders
Car Accident
|
1.0%
1/98 • Number of events 1 • 12 months
|
0.00%
0/102 • 12 months
|
|
General disorders
Detox
|
1.0%
1/98 • Number of events 1 • 12 months
|
3.9%
4/102 • Number of events 4 • 12 months
|
|
General disorders
Residential Substance Use Treatment
|
2.0%
2/98 • Number of events 2 • 12 months
|
4.9%
5/102 • Number of events 6 • 12 months
|
|
General disorders
Injury - Fall
|
3.1%
3/98 • Number of events 3 • 12 months
|
0.00%
0/102 • 12 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place